vs
Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $13.7M, roughly 1.4× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -19.7%, a 95.4% gap on every dollar of revenue. CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-2.1M).
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
CURI vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $13.7M |
| Net Profit | $-3.8M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -17.6% | -86.5% |
| Net Margin | -19.7% | 75.7% |
| Revenue YoY | 35.8% | — |
| Net Profit YoY | -34.6% | 179.1% |
| EPS (diluted) | $-0.07 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $13.7M | ||
| Q3 25 | $18.4M | $19.1M | ||
| Q2 25 | $19.0M | $8.1M | ||
| Q1 25 | $15.1M | $2.9M | ||
| Q4 24 | $14.1M | — | ||
| Q3 24 | $12.6M | — | ||
| Q2 24 | $12.4M | — | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $-3.8M | $10.4M | ||
| Q3 25 | $-3.7M | $-16.3M | ||
| Q2 25 | $784.0K | $-15.8M | ||
| Q1 25 | $319.0K | $-13.3M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-5.0M | — |
| Q4 25 | -17.6% | -86.5% | ||
| Q3 25 | -24.5% | -10.1% | ||
| Q2 25 | 2.5% | -177.7% | ||
| Q1 25 | 0.5% | -472.7% | ||
| Q4 24 | -27.4% | — | ||
| Q3 24 | -25.8% | — | ||
| Q2 24 | -20.6% | — | ||
| Q1 24 | -30.4% | — |
| Q4 25 | -19.7% | 75.7% | ||
| Q3 25 | -20.4% | -85.4% | ||
| Q2 25 | 4.1% | -196.0% | ||
| Q1 25 | 2.1% | -452.7% | ||
| Q4 24 | -19.9% | — | ||
| Q3 24 | -24.3% | — | ||
| Q2 24 | -16.4% | — | ||
| Q1 24 | -42.0% | — |
| Q4 25 | $-0.07 | $-3.74 | ||
| Q3 25 | $-0.06 | $-0.11 | ||
| Q2 25 | $0.01 | $-0.16 | ||
| Q1 25 | $0.01 | $-0.18 | ||
| Q4 24 | $-0.05 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $41.5M | $35.3M |
| Total Assets | $75.7M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $137.5M | ||
| Q3 25 | $27.8M | $103.8M | ||
| Q2 25 | $28.1M | $121.6M | ||
| Q1 25 | $33.4M | $89.1M | ||
| Q4 24 | $32.1M | — | ||
| Q3 24 | $33.2M | — | ||
| Q2 24 | $39.5M | — | ||
| Q1 24 | $38.8M | — |
| Q4 25 | $41.5M | $35.3M | ||
| Q3 25 | $47.2M | $-8.1M | ||
| Q2 25 | $49.8M | $7.1M | ||
| Q1 25 | $58.1M | $10.7M | ||
| Q4 24 | $57.8M | — | ||
| Q3 24 | $62.2M | — | ||
| Q2 24 | $64.8M | — | ||
| Q1 24 | $67.0M | — |
| Q4 25 | $75.7M | $154.7M | ||
| Q3 25 | $74.7M | $133.7M | ||
| Q2 25 | $78.7M | $133.8M | ||
| Q1 25 | $85.3M | $103.7M | ||
| Q4 24 | $86.2M | — | ||
| Q3 24 | $87.6M | — | ||
| Q2 24 | $90.9M | — | ||
| Q1 24 | $94.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-2.0M |
| Free Cash FlowOCF − Capex | $3.9M | $-2.1M |
| FCF MarginFCF / Revenue | 20.5% | -15.3% |
| Capex IntensityCapex / Revenue | 0.1% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-2.0M | ||
| Q3 25 | $4.4M | $-17.5M | ||
| Q2 25 | $2.8M | $-14.5M | ||
| Q1 25 | $1.9M | $29.0M | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $666.0K | — |
| Q4 25 | $3.9M | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | $1.8M | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 20.5% | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | 12.2% | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.1% | 0.7% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.5% | 0.8% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
